GlassScriptPhysician profile
Zoe Nikitas
NPI 1932848660
$6,144.71
in general payments reported to CMS, 2019-2025
21 companies · $3,524 in 2025
The $3,524 reported for 2025 was more than what 97% of Physician Assistant providers received nationally (typical 2025 total: $183).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2022: $81.42 · 2023: $118 · 2024: $2,421 · 2025: $3,524.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $5,613 · Education: $450.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $5,613.04 |
| Education | $450.25 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $1,111.51 | 2024-2025 | |
| Janssen Biotech, INC. | $824.80 | 2024-2025 | Tremfya |
| Genzyme Corporation | $545.19 | 2022-2025 | |
| Arcutis Biotherapeutics, INC. | $534.41 | 2024-2025 | Zoryve |
| Sun Pharmaceutical Industries INC. | $490.62 | 2024-2025 | |
| E.R. Squibb & Sons, L.L.C. | $352.71 | 2024-2025 | Sotyktu |
| Galderma Laboratories, L.P. | $337.09 | 2024-2025 | Nemluvio, Aklief |
| Lilly USA, LLC | $336.25 | 2024-2025 | Taltz, Ebglyss, Olumiant |
| Regeneron Healthcare Solutions, INC. | $293.67 | 2023-2025 | Dupixent |
| Organon LLC | $243.60 | 2024-2025 | Vtama, Hadlima |
| Novartis Pharmaceuticals Corporation | $207.96 | 2024-2025 | |
| Amgen INC. | $189.02 | 2024-2025 | Otezla, Otezla |
| Strata Skin Sciences, INC. | $105.07 | 2024-2025 | Xtrac |
| Pfizer INC. | $104.14 | 2024-2025 | |
| Incyte Corporation | $96.06 | 2025 | Opzelura |
Show all 21 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Sanofi-Aventis U.S. LLC | $92.00 | 2025 | |
| Botanix Sb INC | $84.14 | 2025 | Sofdra |
| Ucb, INC. | $83.38 | 2024-2025 | Bimzelx |
| Sandoz INC. | $69.51 | 2024 | Hyrimoz |
| Leo Pharma INC. | $28.80 | 2024-2025 | Adbry |
| Ortho Dermatologics, A Division of Bausch Health US, LLC | $14.78 | 2025 | Arazlo |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Zoe Nikitas listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.